ET
NBIX icon

Entropy Technologies’s Neurocrine Biosciences NBIX Stock Holding History

Entropy Technologies’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.12M Buy
23,677
+1,154
+5% +$153K 0.14% 194
2025
Q4 		$3.19M Buy
+22,523
New +$3.26M 0.17% 165

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Entropy Technologies's NBIX Position: Q1 2026 in Review

Entropy Technologies increased its Neurocrine Biosciences (NBIX) stake by 5.1% in Q1 2026, buying an estimated $153K and bringing the position to 23,677 shares worth $3.12M. The position accounts for 0.14% of the portfolio, ranked #194.

Entropy Technologies first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.19M in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Entropy Technologies held 23,677 shares of Neurocrine Biosciences worth $3.12M as of Q1 2026.
  • Entropy Technologies bought 1,154 Neurocrine Biosciences shares in Q1 2026, an estimated $153K.
  • Neurocrine Biosciences made up 0.14% of Entropy Technologies's portfolio in Q1 2026, its #194 holding.
  • Entropy Technologies first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Entropy Technologies's Neurocrine Biosciences position peaked at $3.19M in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.